Cargando…
Pharmacological and Behavioral Characterization of D-473, an Orally Active Triple Reuptake Inhibitor Targeting Dopamine, Serotonin and Norepinephrine Transporters
Major depressive disorder (MDD) is a debilitating disease affecting a wide cross section of people around the world. The current therapy for depression is less than adequate and there is a considerable unmet need for more efficacious treatment. Dopamine has been shown to play a significant role in d...
Autores principales: | Dutta, Aloke K., Santra, Soumava, Sharma, Horrick, Voshavar, Chandrashekhar, Xu, Liping, Mabrouk, Omar, Antonio, Tamara, Reith, Maarten E. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245125/ https://www.ncbi.nlm.nih.gov/pubmed/25427177 http://dx.doi.org/10.1371/journal.pone.0113420 |
Ejemplares similares
-
The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats
por: Zhang, Renyu, et al.
Publicado: (2014) -
Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors
por: Paudel, Suresh, et al.
Publicado: (2021) -
Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021) -
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010) -
Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009)